ClinicalTrials.gg
Not yet recruitingNCT07941011Updated Nov 19, 2026

Hyaluronic Acid Barrier in Parotidectomy

An interventional study of Axoguard HA+ Nerve Protector and Parotidectomy in Parotidectomy, Patient-reported Outcomes, Parotid Cancer and Parotid Gland Tumor, sponsored by Milton S. Hershey Medical Center. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Milton S. Hershey Medical Center · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy of AxoGuard HA+ (hyaluronic acid nerve protector) in preventing Frey syndrome following parotidectomy. A parotidectomy is a surgical procedure to remove all or part of the parotid gland, the largest salivary gland located near the ear and jaw. The specific aims are to determine whether placement of AxoGuard HA+ during parotidectomy can significantly reduce both clinical and subclinical incidence of Frey syndrome compared to standard surgical technique alone.

02

Conditions studied

  • Parotidectomy, Patient-reported Outcomes
  • Parotid Cancer
  • Parotid Gland Tumor
  • Parotidectomy
  • Frey's Syndrome

Browse trials for

03

In context

Parotid Neoplasms

28 studies on the registry are indexed under Parotid Neoplasms; 8 are open to participants now.

This study's planned enrollment of 20 is below the median of 50 across 19 interventional studies indexed under Parotid Neoplasms.

Browse Parotid Neoplasms studies →

Lead sponsor

Milton S. Hershey Medical Center is the lead sponsor of 493 studies on the registry; 60 are open to participants now.

Of its 58 completed or terminated interventional studies of FDA-regulated products, 46 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years) undergoing parotid surgery for benign parotid masses
  • Able to provide for study participation.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding patients
  • Known allergy to hyaluronic acid products
  • Previous parotid surgery or radiation
  • Patients with known sensitivity to porcine, alginate, or hyaluronate materials.
  • Known allergy to iodine.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
20 participants (estimated)

Study arms

  • Placebo comparator
    Parotidectomy

    Parotidectomy - Standard of Care

    Procedure: Parotidectomy

  • Experimental
    Parotidectomy with Axoguard HA+ Nerve Protoector

    Parotidectomy - With use of nerve protector

    Device: Axoguard HA+ Nerve Protector

Interventions

  • DeviceAxoguard HA+ Nerve Protector

    AxoGuard HA+ nerve protector is an FDA-approved device available for clinical use, but its specific efficacy in preventing Frey syndrome following parotidectomy has not been systematically evaluated in controlled trials.

  • ProcedureParotidectomy

    A parotidectomy is a surgical procedure to remove all or part of the parotid gland, the largest salivary gland located near the ear and jaw.

06

What researchers measure

Primary outcomes

  1. Number of subjects with positive Starch-Iodine test

    Time frame: 3 months post-op

Secondary outcomes

  1. Number of subjects with positive Starch-Iodine test

    Time frame: 12 months post-op

  2. Number of subjects experiencing a reduction in clinically reported symptoms of Frey Syndrome

    Facial sweating, flushing, warmth/burning sensation, tingling/prickling, itching, and symptoms associated with chewing.

    Time frame: 1 month pot-op

  3. Number of subjects experiencing a reduction in clinically reported symptoms of Frey Syndrome

    Facial sweating, flushing, warmth/burning sensation, tingling/prickling, itching, and symptoms associated with chewing.

    Time frame: 3 months pot-op

  4. Number of subjects experiencing a reduction in clinically reported symptoms of Frey Syndrome

    Facial sweating, flushing, warmth/burning sensation, tingling/prickling, itching, and symptoms associated with chewing.

    Time frame: 12 months pot-op

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Jan 31, 2029
CompletionEst.
Jan 31, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
3 edited
What changed in the outcomes
  • EditedNumber of subjectsubjects experiencing a reduction in clinically reported symptoms of Frey SyndromeTime frame: 1 month pot-op
  • EditedNumber of subjectsubjects experiencing a reduction in clinically reported symptoms of Frey SyndromeTime frame: 3 months pot-op
  • EditedNumber of subjectsubjects experiencing a reduction in clinically reported symptoms of Frey SyndromeTime frame: 12 months pot-op
Nov 19, 2026
Registered
First appeared on the registry
Nov 17, 2026
Show all 2 updates
  1. Nov 19, 2026
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditedNumber of subjectsubjects experiencing a reduction in clinically reported symptoms of Frey SyndromeTime frame: 1 month pot-op
    • EditedNumber of subjectsubjects experiencing a reduction in clinically reported symptoms of Frey SyndromeTime frame: 3 months pot-op
    • EditedNumber of subjectsubjects experiencing a reduction in clinically reported symptoms of Frey SyndromeTime frame: 12 months pot-op
  2. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941011
Collaborators
Axogen Corporation
Responsible party
Neerav Goyal (Professor of Otolaryngology - Head and Neck Surgery, Neurosurgery, and Public Health Sciences, Milton S. Hershey Medical Center) — Principal investigator
First posted
Nov 17, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jan 31, 2029 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Bailey Swaffar
Contact
bswaffar@pennstatehealth.psu.edu
717-531-1614
Shwetha Srikanth
Contact
ssrikanth@pennstatehealth.psu.edu
717-531-0003 ext. 287291
Neerav Goyal
principal investigator · Milton S. Hershey Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion